Curated News
By: NewsRamp Editorial Staff
September 10, 2026
Optimi Health to Launch Phase 2 Psilocybin Trial for Depression
TLDR
- Optimi Health owns exclusive Phase 2 psilocybin trial results, offering a strategic edge in the emerging psychedelic pharmaceutical market.
- Optimi Health's Phase 2 trial will enroll up to 200 participants across Canadian sites, testing a single supervised dose of naturally derived psilocybin.
- Optimi Health's trial aims to advance psilocybin therapy for major depressive disorder, potentially improving mental health treatment options.
- Optimi Health plans a 2027 Phase 2 trial of psilocybin for depression, with dosing expected to finish by year-end.
Impact - Why it Matters
This news matters because it signals a major step forward in the clinical validation of psilocybin as a treatment for major depressive disorder, a condition affecting millions worldwide. If successful, Optimi’s trial could pave the way for regulatory approval and broader patient access to psychedelic-assisted therapies, offering new hope for those who have not responded to conventional treatments. The company’s GMP-grade manufacturing and existing distribution channels in Australia and Canada position it as a key player in the emerging psychedelic pharmaceutical market, potentially accelerating the integration of these therapies into mainstream mental health care.
Summary
Optimi Health Corp., a commercial-stage pharmaceutical company specializing in GMP-grade psychedelic drug products, has announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder (MDD) in the first half of 2027. The Health Canada-authorized trial will enroll up to 200 participants across multiple Canadian sites and assess the safety and efficacy of a single supervised dose of Optimi’s naturally derived psilocybin, manufactured at its GMP facility. Optimi will exclusively own the trial results and intends to provide periodic interim safety and efficacy readouts, with full topline results expected after dosing and follow-up evaluations are complete. The company stated that the study represents an initial step toward potential registration and can be funded with current cash on hand.
Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) is a Health Canada-licensed manufacturer producing validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia. Its products are currently prescribed to patients in Australia under the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. The trial marks a significant advancement in the clinical development of psychedelic-assisted therapies for depression.
The news was disseminated on behalf of Optimi Health Corp. and may include paid advertising. For more information, visit the full press release at https://ibn.fm/ZLlie. The announcement was distributed via NetworkNewsWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Optimi Health to Launch Phase 2 Psilocybin Trial for Depression
